scholarly journals Life-threatening right atrial thrombus in a premature newborn successfully treated with recombinant tissue plasminogen activator

2018 ◽  
Vol 4 (2) ◽  
Author(s):  
Wendy Dewals ◽  
Abraham Benatar
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Recombinant Tissue Plasminogen Activator ◽  
Right Atrial ◽  
Atrial Thrombus ◽  
Premature Newborn ◽  
Tissue Plasminogen ◽  
Life Threatening ◽  
Right Atrial Thrombus

Ultrasound-assisted lysis using recombinant tissue plasminogen activator and the EKOS EkoSonic endovascular system for treating right atrial thrombus and massive pulmonary embolism: A case study

2014 ◽  
Vol 30 (10) ◽  
pp. 739-743 ◽  
Author(s):  
NW Shammas ◽  
R Padaria ◽  
G Ahuja
Keyword(s):  
Pulmonary Embolism ◽  
Case Report ◽  
Plasminogen Activator ◽  
Pulmonary Embolus ◽  
Massive Pulmonary Embolism ◽  
Right Atrial ◽  
Atrial Thrombus ◽  
Tissue Plasminogen ◽  
Ultrasound System ◽  
Right Atrial Thrombus

Objective Right atrial thrombus in the setting of a large pulmonary embolus is rare and is associated with serious adverse events. This case report presents the role played by EKOS EkoSonic ultrasound system in successfully treating right atrial thrombus and massive pulmonary embolism. Case report A 69-year-old female presented with a massive pulmonary embolus and a large mobile right atrial thrombus. She was treated with catheter-directed lysis using the EKOS EkoSonic ultrasound system and tissue plasminogen activator, with complete resolution of her right atrial thrombus and a marked improvement in her pulmonary embolus and hemodynamics. Conclusion This case report provides a new and an effective option to treat right atrial thrombus associated with a large pulmonary embolus leading to a good outcome.

scholarly journals Hypersensitivity reactions to recombinant tissue plasminogen activator

2019 ◽  
pp. practneurol-2018-002189
Author(s):  
Vafa Alakbarzade ◽  
Declan O’Kane ◽  
Anthony C Pereira
Keyword(s):  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Thrombolytic Agent ◽  
Recombinant Tissue Plasminogen Activator ◽  
Response Monitoring ◽  
Hypersensitivity Reactions ◽  
Tissue Plasminogen ◽  
Life Threatening ◽  
Basic Biology ◽  
Anaphylactic Response

Recombinant tissue plasminogen activator (rtPA) is currently the only approved thrombolytic agent for treating acute ischaemic stroke that is widely used in clinical practice. However, it may cause haemorrhage and hypersensitivity reactions. Orolingual angioedema is an infrequent, usually mild but potentially life threatening, hypersensitivity reaction to rtPA. Our understanding of the basic biology of angioedema has increased in recent years. There is growing evidence that rtPA-induced orolingual angioedema is driven mainly by bradykinin generation rather than it being an anaphylactic response. Monitoring is important because orolingual angioedema may evolve and compromise airways and a small number do have angioedema as part of systemic anaphylaxis. There are no published guidelines for treating rtPA-induced orolingual angioedema, although some evidence suggests that those refractory to standard antianaphylactic agents may resolve with bradykinin B2 receptor antagonists. It is important that responses to orolingual angioedema are proportionate and that patients are closely monitored.

Sign in / Sign up

Export Citation Format

Share Document